Moleculin Reports Dosing of Novel Brain Cancer Drug WP1066 in P-I trial for the treatment of Brain Tumor

Shots:

• The P-I trial is assessing WP1066 in 15 patients with relapsed brain tumor for 6 to 8mos, testing its safety and tolerability in patients at MD Anderson Cancer Centre
• WP1066 a novel STAT3i (originated from active ingredient in propolis) has shown promising results in animal studies inhibiting tumor growth with improvement in survival
• Mayo Clinic and Emory University is also evaluating WP1066 in pediatric brain tumor trials
• WP1066 inhibits STAT3 (a supporter of survival and growth of tumor cells, evasion of the immune response and metastasis to distant organs) and producing anti-cancer effects in patients

Click here to read full press release/ article | Ref: Moleculin | Image: The street